Overview

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Treatments:
Carboplatin
Cisplatin
Cytarabine
Dexamethasone
Etoposide
Gemcitabine
Ifosfamide
Oxaliplatin
Rituximab
Vinorelbine